Novo Nordisk says it does. The company has not published a score for that finding, or said how it measured it.
Food noise is the part of appetite that does not switch off when you eat. You read the same paragraph three times because you are thinking about what is in the fridge. You finish a meal and start planning the next one. For people who live with that, the change they describe first on a GLP-1 drug is not the scale. It is the quiet.
The phrase started in forums, mostly from people on semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. On September 30, 2026 it turned up in a drug company's announcement. Novo Nordisk said CagriSema "reduced food noise", along with cravings, hunger, appetite and food-related thoughts, in a 52-week study using functional MRI brain scans.1
What is actually in the announcement?
It carries three separate findings and one weight figure. Nothing else in it has a measurement attached.
The announcement reports which direction everything moved and almost never how far. Gathered in one place, it contains no count of how many people were scanned, no brain region named, no effect size or activation value or statistic for the imaging, no instrument named for any eating-behaviour measure, no score or baseline change or placebo comparison for hunger, craving or food noise, no numeric fat reduction for the abdomen, liver or pancreas, and no bone marker named, no bone density and no fractures.1
The secondary coverage adds none of it, because there is nothing further to add.4 One number appears in the release, a weight figure, and it is labelled two different ways in the same sentence.
What did the brain scan actually measure?
The scan showed how people's brains responded to photographs of food, and that sits one step away from wanting it.
The study ran 52 weeks in adults with overweight or obesity and was presented as a late-breaking abstract at EASD 2026, where it received a Best Abstract Award. Novo reports that CagriSema "modified brain responses to high-calorie food cues" in regions tied to cravings, reward, sensory processing and behavioural control.1
Some credit is due before any of the criticism. A 22.4% weight result at 52 weeks is a large effect by the standards of this field. Scanning people's brains over a year to chase a question about their own thoughts is an expensive, serious attempt at something most companies never try to measure, and the award was not given for nothing. What is thin here is the reporting, not the work.
A scan can only take this so far, because food-cue reactivity is a surrogate. A change in how a brain region responds to a photograph of a doughnut shows that something shifted in processing. It does not show that anyone's head got quieter. The questionnaires come closer to that, and they were reported without numbers.
Why would a weight-loss drug change food thoughts at all?
It pushes on two appetite hormones at once, and then there is one unproven step at the end.
Amylin is released from the pancreas alongside insulin and acts on the hindbrain to signal that eating can stop. GLP-1 drugs act at the GLP-1 receptor, slow gastric emptying and reduce appetite. CagriSema combines an amylin analogue, cagrilintide, with semaglutide, so it pushes on both.
Both of those are appetite mechanisms. Food noise describes thought content instead, a different level of description altogether. Something that makes you less hungry is not automatically something that stops you thinking about food, and plenty of people have experienced the two coming apart in both directions.
The imaging study exists to bridge that gap, and the regions it names are the ones you would want it to name. Nobody has finished building the bridge. Getting from a changed response to a food photograph to a quieter head is the step with no number attached to it.
Can food noise be measured at all?
Someone has built an instrument for it, so the claim can be checked.
Until recently there was no instrument for it. The protocol for the first attempt states the position plainly: "Currently, there are no validated questionnaires to assess food noise."2 That study, run at Pennington Biomedical Research Center with co-investigators from WW International, defined food noise as "constant, intrusive thoughts about food that are disruptive to daily life and make healthful behaviors extremely difficult," generated 10 to 15 candidate items and reduced them to roughly 6 to 8, and tested them in a 400-person sample with a test-retest subsample and a separate construct-validity subsample.2 A validated Food Noise Questionnaire has since been published in Obesity.3
Novo's release does not say whether that instrument, or any other, was used. It lists food noise in a sequence with cravings, hunger, appetite and food-related thoughts. That reads more like a plain-language gloss on several measures than a result from a named scale.1
Both readings are available and the release does not settle which is right. Either CagriSema was tested against a validated food noise measure, in which case the company had every reason to name it, or it has borrowed a community phrase to describe questionnaire data about hunger and craving. The abstract or a full publication will say. The press release does not.
What did people report about hunger and cravings?
They reported less of all of it, at two points across the year, in words instead of numbers.
Novo reports that CagriSema "substantially improved eating behaviour" and that participants reported less hunger, less appetite, fewer food-related thoughts and fewer cravings, with better craving control, at both week 22 and week 52.1
These are the measures that come closest to what someone means when they say the noise stopped, and they are the ones a reader can hold against their own week. Imaging is a research tool. A craving questionnaire is a description of a Thursday.
This is the gap that matters most, more than the missing scan values. The result closest to the reader's own experience is reported here as an adjective.
Does the food noise come back, and how long does it last?
Nobody has measured it, and the reports go both ways.
Accounts from people taking drugs in this class fall into a few patterns. The quiet arrives within the first weeks and is the change they notice before any weight moves. It thins out as a dose stops being new, often described alongside a weight plateau, and returns to some degree in the days before the next injection. It comes back after stopping the drug. For some it never arrives at all, including people whose weight falls anyway.
Those reports are not evidence about the drug and they are not nothing. They describe what people experienced, and the useful thing this page can tell you is that no trial has measured any of it. The 52-week study reported eating-behaviour measures at week 22 and week 52, both while people were still taking the drug.1 It published nothing from after treatment stopped, so there is no trial result to set against the people who say the quiet ended when the drug did.
That gap matters more here than it would for a weight figure. Weight after stopping has been studied across this class. Food noise after stopping has not been studied in CagriSema at all.
What did the organ fat study show?
Fat fell in three places that matter: the abdomen, the liver and the pancreas.
This is a different trial from the brain study. REIMAGINE 1 is a phase 3a trial in adults with early type 2 diabetes, and it enrolled 189 people. Its MRI sub-study found that CagriSema 2.4 mg/2.4 mg produced significant reductions against placebo at all three sites over 40 weeks, alongside a 14.3% body-weight reduction at week 40.1 Abdominal fat here means visceral fat, the fat around the organs rather than under the skin.
Liver fat is normally reported as a percentage change or an absolute percentage point change, because the thresholds that matter clinically are specific ones. For all three sites the release gives "significant" and stops.1
Does CagriSema cause bone loss?
The analysis is a post hoc look at blood markers, and bone itself was never measured.
Rapid weight loss reduces bone mineral density. Bone loss is asked about for every drug in this class for that reason. That is a live question for every drug in this class, and it is the reason this analysis exists. The finding comes from REIMAGINE 2, a trial of 2,713 adults with inadequately controlled type 2 diabetes, and the bone work is a post hoc analysis of bone markers over 68 weeks. Novo reports "signs of healthy balance in bone maintenance" alongside a 14.2% body-weight reduction, and the investigators describe the result as "preliminary reassurance regarding bone changes."1
Blood markers are a reasonable early look. The measurement people are asking about is bone mineral density, and this analysis does not contain it.1
That makes the finding a reason to keep watching, not a reason to stop worrying. The investigators' own word for it is preliminary, and that word should travel with it wherever it gets quoted.
How many studies are being reported here?
There are three, run in two different patient populations over three different durations.
| Brain study | REIMAGINE 1 MRI sub-study | REIMAGINE 2 bone analysis | |
|---|---|---|---|
| Population | Overweight or obesity | Early type 2 diabetes | Type 2 diabetes, inadequately controlled |
| Parent trial size | Not stated | 189 | 2,713 |
| Number analysed | Not stated | Not stated | Not stated |
| Duration | 52 weeks | 40 weeks | 68 weeks |
| Design | Prespecified study, late-breaking abstract | Sub-study | Post hoc analysis |
| Weight result quoted | 22.4% | 14.3% | 14.2% |
Set out that way, the weight figures stop looking inconsistent. A 22.4% result in people without diabetes and a 14.3% result in people with it is the ordinary pattern for this drug class, not a contradiction, and the durations differ by 28 weeks across the three.
The programme names need keeping straight, because the site has covered the other one. REDEFINE is the obesity programme, and our coverage of REDEFINE 4 against tirzepatide deals with that. REIMAGINE is the type 2 diabetes programme, and two of these three findings come from it.
What is the 22.4% figure?
The release describes it two ways in one sentence, and they are not the same claim.
Novo reports the brain findings as "associated with a 22.4% body-weight reduction versus placebo at 52 weeks (estimated treatment difference, p<0.0001)."1 A 22.4% reduction and an estimated treatment difference of 22.4 percentage points against placebo are different numbers, because the second implies an absolute reduction larger than the first by however much the placebo group lost.
The secondary coverage split on it, with one outlet describing it as a difference and another quoting it as a reduction.4 Nothing in the release resolves which is meant. Our REDEFINE 4 coverage carries the weight figures from the pivotal trials. Those are the ones to use for the size of CagriSema's effect until this one is clarified.
When does the FDA decide?
A decision is expected in the fourth quarter of 2026. That timing is company guidance and not a confirmed date.
Novo filed a New Drug Application with the FDA in December 2025 for weight management, and submitted to Health Canada in the same month. A high-dose trial of CagriSema at 2.4 mg/7.2 mg started during 2026.1 CagriSema is not approved anywhere as of the date on this page.
When are food thoughts something other than appetite?
Intrusive thinking about food is also a feature of restriction and of eating disorders, and a drug that quietens it can hide that.
Constant thoughts about food are one of the most reliable consequences of not eating enough. That is true whether the under-eating is deliberate, accidental or a side effect of a drug that removed the signal telling you to eat. A medication that quietens the thoughts while the under-eating continues has not fixed anything; it has removed the alarm.
Raise these with a clinician instead of working them out alone: food thoughts that come with guilt, secrecy or a sense of losing control around eating; eating so little that you are dizzy, cold, losing hair or missing periods; or relief at not eating that feels like the point rather than a side effect.
If any of that is familiar, the National Alliance for Eating Disorders runs a helpline staffed by clinicians, and a GP or prescriber can refer. Nothing on this page is a reason to adjust what you are taking.
What does this mean for what is being sold?
Very little, because the product in these studies is not what research sellers list.
CagriSema in the trials is a single co-formulation holding cagrilintide and semaglutide at a fixed ratio, given once a week. In our October 10 capture, CagriSema as a named product appeared in only 5 listings across 4 sellers, at a median of $7.90 per mg. The two components separately are everywhere: cagrilintide in 110 listings across 73 sellers at a median of $11.80 per mg, and semaglutide in 179 listings across 85 sellers at $7.00 per mg.5
So most people assembling this themselves are buying two vials and choosing their own ratio. The 52-week brain and eating-behaviour findings describe a fixed co-formulation at a known dose, in people who were scanned, questioned and monitored for a year. Two vials combined at a ratio of your own choosing is a different thing, and nothing in this announcement describes it.
Common questions
Does CagriSema work for food noise?
Novo Nordisk says it does, in a 52-week study using functional MRI, reported on September 30, 2026. The company has published no score for that finding and has not named the instrument used to measure it. A validated Food Noise Questionnaire now exists, and the release does not say whether it was used.
What is food noise?
The term describes constant, intrusive thoughts about food that disrupt daily life. That wording comes from the protocol of the first study to build a validated questionnaire for it. The same protocol recorded that no validated measure existed before then.
Did the brain scan show less craving?
It showed changed brain responses to pictures of high-calorie food in regions associated with craving, reward, sensory processing and behavioural control. Novo named no region, gave no effect size and published no imaging values. Food-cue reactivity is a surrogate for the experience of craving and not a direct measure of it.
How much weight did people lose in the brain study?
The release gives 22.4% at 52 weeks and describes it both as a reduction versus placebo and as an estimated treatment difference. Those are different claims. Our REDEFINE coverage carries the weight figures from the pivotal trials.
Does CagriSema reduce liver fat?
The REIMAGINE 1 MRI sub-study reported significant reductions in fat in the abdomen and around the liver and pancreas against placebo at 40 weeks. No numeric reduction was given for any of the three sites, and the number of people scanned was not stated.
Does CagriSema cause bone loss?
The available analysis does not answer that. It is a post hoc look at bone markers in REIMAGINE 2 over 68 weeks, reporting signs of healthy balance in bone maintenance. It names no markers, reports no bone mineral density and reports no fractures, and the investigators call it preliminary.
Is CagriSema approved?
No. Novo filed with the FDA in December 2025 for weight management and a decision is expected in the fourth quarter of 2026, on company guidance rather than a confirmed date. It is approved nowhere as of the date on this page.
Is CagriSema the same as cagrilintide plus semaglutide?
In the trials it is one co-formulation at a fixed ratio, given once weekly. Buying the two components separately and combining them is not the same product, and the ratio is then a choice rather than a specification.
Does food noise come back on CagriSema?
No trial has measured it. The 52-week study reported eating-behaviour measures at weeks 22 and 52, both during treatment, and published nothing from after treatment stopped. People taking drugs in this class report the quiet thinning late in a dosing week and returning on stopping, and there is no trial result to set against that.
How could a weight-loss drug change food thoughts?
CagriSema combines an amylin analogue with semaglutide. Amylin acts on the hindbrain to signal that eating can stop, and GLP-1 drugs reduce appetite and slow gastric emptying. Both are appetite mechanisms, and the step from appetite to thought content is the part nobody has published a number for.
Can food noise mean something other than hunger?
Yes. Constant thoughts about food are one of the most reliable consequences of not eating enough, and intrusive thinking about food is also a feature of eating disorders. A drug that quietens the thoughts while under-eating continues has removed a signal rather than solved a problem.
Which programme are these results from?
REIMAGINE is the type 2 diabetes programme and two of the three findings come from it. REDEFINE is the obesity programme, covered in our REDEFINE 4 piece. The brain study sits outside both names in the release.
Have these findings been peer reviewed?
Not as published results. The brain study was a late-breaking conference abstract, the organ fat result a sub-study and the bone result a post hoc analysis, all reported through a company announcement.
Sources
- Novo Nordisk. Novo's investigational obesity and diabetes drug CagriSema reduces 'food noise' and shows benefits in organ and bone health. Company announcement, Bagsværd, September 30, 2026, presented at EASD 2026. novonordisk.com. Read at source. Company announcement covering three separate pieces of work, not a peer-reviewed publication. 52-week functional MRI study in adults with overweight or obesity (Uhre et al., late-breaking abstract, Best Abstract Award at EASD 2026): states CagriSema modified brain responses to high-calorie food cues in regions tied to cravings, reward, sensory processing and behavioural control; participant number not stated; no brain regions named; no imaging values, effect sizes or statistics given for the fMRI result. States CagriSema substantially improved eating behaviour and reduced food noise, cravings, hunger, appetite and food-related thoughts and improved craving control at weeks 22 and 52; no instrument named and no scores given. Reports the brain findings as associated with a 22.4% body-weight reduction versus placebo at 52 weeks, labelled in the same sentence as an estimated treatment difference, p<0.0001. REIMAGINE 1 MRI sub-study (Pratley et al.), phase 3a in early type 2 diabetes, parent trial 189 adults, 40 weeks: significant reductions in fat in the abdomen and around the liver and pancreas versus placebo, with no numeric values; body weight down 14.3% at week 40; sub-study size not stated. REIMAGINE 2 post hoc bone marker analysis (Haluzík et al.), parent trial 2,713 adults with inadequately controlled type 2 diabetes, 68 weeks: signs of healthy balance in bone maintenance, described by the authors as preliminary reassurance regarding bone changes; no markers named, no bone mineral density, no fracture data, number analysed not stated; body weight down 14.2% at week 68. Regulatory: NDA filed with the FDA in December 2025 for weight management, decision expected in Q4 2026, submission to Health Canada in December 2025, and a CagriSema 2.4 mg/7.2 mg phase 3 trial started in 2026.
- Martin CK (principal investigator). Development and Validation of a Brief Food Noise Questionnaire. Pennington Biomedical Research Center, with co-investigators from WW International. NCT06315907. Protocol PDF. Protocol read at source. States "Currently, there are no validated questionnaires to assess food noise." Defines food noise as "constant, intrusive thoughts about food that are disruptive to daily life and make healthful behaviors extremely difficult." Online survey design: 400-person initial sample, 150-person test-retest subsample at about 7 days, 250-person construct validity subsample, with expert and layperson content review then exploratory and confirmatory factor analysis. Approximately 10 to 15 candidate items to be reduced to about 6 to 8; Table 1 lists the questionnaire at 8 items, and the protocol does not confirm the final count. Cited for the definition of food noise and for the absence of a validated measure before this work.
- Diktas H, et al. Development and validation of the Food Noise Questionnaire. Obesity, 2025. DOI 10.1002/oby.24216. Not read. The journal page would not load, so this is cited only for the existence of a published, validated instrument whose development the protocol above describes. No figure, item count or validation statistic from this paper is used on this page.
- Patient Care Online. CagriSema alters food-cue responses, reduces organ fat in new analyses. patientcareonline.com. Read at source. Secondary coverage, cited only to show that the 22.4% figure was reported inconsistently: this article describes it as an estimated treatment difference versus placebo while quoting Novo calling it a reduction. Confirms that no participant count for the fMRI study, no named instruments, no numeric brain or eating-behaviour results, no named brain regions, no numeric organ fat reductions and no named bone markers were available beyond the company release.
- Peptide Decoding vendor price capture, October 10, 2026. peptidedecoding.com/prices. Our own data, counting one priced product at one seller as a listing. 165 tracked sellers and 8058 recorded listings in that capture. CagriSema as a named product: 5 listings across 4 sellers, median $7.90 per mg among in-stock single vials. Cagrilintide: 110 listings across 73 sellers, median $11.80 per mg. Semaglutide: 179 listings across 85 sellers, median $7.00 per mg.
Citing this page. Peptide Decoding. Does CagriSema Reduce Food Noise? What the Brain Scan Actually Measured. Findings from Novo Nordisk's company announcement of September 30, 2026; food noise definition from NCT06315907; listing data from the October 10, 2026 capture. https://peptidedecoding.com/guides/cagrisema-food-noise